ClinicalTrials.gg
RecruitingNCT07740707Updated Nov 17, 2026

Short-term SCS for Refractory Diabetic Foot Neuropathic Pain

An interventional study of Standardized Routine Diabetic Foot Therapy and Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation in Refractory Diabetic Foot Neuropathic Pain, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 17, 2026Now RecruitingFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Diabetic Foot with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Diabetic Foot · China.

Planned enrollment
16th of 41
88 · median 70
Started
2026
with 5 others
No phase
16 of 52
9 open now
Primary completion
2027-03
later than 16 of 23 live
Registered
49th of 52
by date

Among the 52 studies in Diabetic Foot with a site in China, this one is the 16th largest by planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 16 of the 23 other live ones, and was the 49th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

21 of the 52 studies in Diabetic Foot with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Diabetic Foot with a site in China, or all of them as a file.
02

Study summary

This single-center, assessor-blinded randomized controlled trial enrolls 88 patients with drug-refractory diabetic foot neuropathic pain unsuitable for revascularization surgery. Participants are randomized 1:1 to receive standard diabetic foot care alone (control) or standard care plus 14-day short-term spinal cord stimulation (intervention). The primary outcome is pain remission rate at 6 months, with repeated assessments of microcirculation, nerve function, quality of life and adverse events over 6 months. This study evaluates the efficacy and safety of short-term spinal cord stimulation and develops standardized clinical protocols for this minimally invasive therapy.

03

Conditions studied

  • Refractory Diabetic Foot Neuropathic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Confirmed type 2 diabetes mellitus, Wagner grade 1-3 diabetic foot;
  3. Persistent moderate-to-severe neuropathic pain (Numeric Rating Scale, NRS ≥4) after ≥3 months of standardized conservative treatment including glycemic control, neurotrophic drugs, multi-modal analgesia and wound care;
  4. to lower extremity revascularization surgery, persistent pain after revascularization, or voluntary refusal of vascular surgery;
  5. Clear consciousness, capable of completing scale assessments and multi-timepoint follow-up;
  6. Voluntary participation with signed written .

Exclusion criteria

Exclusion Criteria:

  1. Spinal deformity, spinal infection, intraspinal tumor or history of spinal surgery, precluding epidural electrode implantation;
  2. Severe coagulation disorders, systemic infection or uncontrolled severe active foot infection;
  3. Severe dysfunction of heart, liver, kidney or respiratory system, unable to tolerate minimally invasive operation;
  4. Previous spinal cord stimulation or peripheral nerve destructive surgery;
  5. Psychiatric disorders interfering with assessment and follow-up cooperation;
  6. Pregnant or lactating women;
  7. Concurrent enrollment in other clinical trials targeting diabetic foot or chronic pain interventions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation

    Patients received stSCS in addition to standard routine therapy

    Procedure: Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation

  • Experimental
    Standardized Routine Diabetic Foot Therapy

    Patients receive standardized routine treatment for diabetic foot

    Drug: Standardized Routine Diabetic Foot Therapy

Interventions

  • DrugStandardized Routine Diabetic Foot Therapy

    No spinal cord stimulation intervention; unified comprehensive clinical management throughout follow-up: 1. Precise glycemic control: Adjustment of oral hypoglycemic agents or insulin, regular HbA1c monitoring; 2. Basic medication: Neurotrophic agents, lower limb microcirculation improvers, stepwise multi-modal analgesics; 3. Standardized wound care: Debridement, dressing change and foot decompression; 4. Health education: Diabetic diet guidance, foot self-care training and individualized exercise advice; 5. Unified follow-up visits at 14 days, 1 month, 3 months and 6 months for indicator detection and adverse event documentation.

  • ProcedureStandard Routine Therapy + 14-day Short-term Spinal Cord Stimulation

    All routine management identical to the control group, with additional 14-day reversible epidural SCS intervention: 1. Epidural electrode implantation targeting T10-T12 spinal segments under local anesthesia; 2. Standardized stimulation parameters set in accordance with domestic clinical guidelines for spinal cord stimulation; electrodes retained for 14 days and removed after the intervention period; 3. Identical follow-up schedule and assessment indicators as the control group.

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) score

    The primary outcome was pain intensity measured by the NRS(0-10) recorded at baseline, immediately after stimulation termination (study group)/at the corresponding time point after treatment (control group), and at 1, 3, and 6 months post-treatment. The proportions of patients with an NRS reduction of ≥30% and ≥50% from baseline were also recorded, with the latter defined as treatment response. NRS ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate worse pain.

    Time frame: Six months

Secondary outcomes

  1. Change in Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI)

    The PSQI total score ranges from 0 to 21. Higher scores indicate worse sleep quality

    Time frame: Six months

  2. Change in Physical Health assessed by the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS)

    The SF-36 PCS score ranges from 0 to 100. Higher scores indicate better physical health

    Time frame: Six months

  3. Change in Mental Health assessed by the 36-Item Short Form Health Survey Mental Component Summary (SF-36 MCS)

    The SF-36 MCS score ranges from 0 to 100. Higher scores indicate better mental health

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 7 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Aug 3, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in China
Show site
  • Nanchong Central Hospital · Nanchong, China
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Nanchong Central Hospital · Nanchong, China
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07740707
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Aug 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Zhenguo Gao
Contact
gaozhenguo0822@163.com
+8618404999336

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion